Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing disclosure of this potential conflict of interest.
Academic rigour, journalistic flair
Articles on Pharmaceutical industry
Displaying 1 - 20 of 59 articles
Both Trump and Harris seek to lower drug costs for patients. What headway have they made on realizing this goal?
Direct advertising of branded prescription drugs can lead patients to seek unnecessary medicines and treatments. Repealing the current law could help prevent this, and reduce health spending.
Cancer patients will benefit from the investment but so will people with other health conditions because the funding also covers medicines that Pharmac ranked as more important.
We suspect these drug company payments are just the tip of the iceberg.
Growing evidence shows industry payments to doctors play a key role in unethical pharmaceutical marketing. New Zealand’s disclosure scheme fails to capture all companies and payment types.
Horseshoe crabs play a unique role in medicine, but they’re also ecologically important in their home waters along the Atlantic coast. Can regulators balance the needs of humans and nature?
A national procurement program for essential medicines could provide a principled, evidence-based solution to the current challenges facing a national pharmacare program in Canada.
Pharmaceutical and insurance industries that could lose profit through lower drug prices are not happy that a pharmacare bill is planned for fall. They are speaking out and mobilizing their allies.
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
An anthropology course explores how peoples and cultures around the world use nature-based medicines to heal.
Some commercial products and practices are directly linked to avoidable ill health, planetary damage, and social and health inequity. Large transnational corporations are especially to blame.
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Changes to Canada’s Patented Medicine Prices Review Board regulations have been postponed for a fourth time in two years as Canadians continue to pay some of the highest drug prices in the world.
When drugs are taken off the market because they are either unsafe or don’t work, do pharma companies admit that there are problems? Or do they deny the evidence?
If no action is taken to address antibiotic resistance, infections from multidrug-resistant bacteria could cause 10 million deaths each year by 2050.
New payment models may mean more of the people who need these treatments can get them.
The COVID pandemic is giving drug companies an opportunity to reset their image. So how did they get so big and their credibility sink so low?
Top contributors
-
Joel Lexchin is a Friend of The Conversation.Professor Emeritus of Health Policy and Management, York University, Canada
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Assistant Professor, Bond University
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Associate Professor in Psychological Medicine, University of Auckland, Waipapa Taumata Rau
-
Professor, School of Population and Public Health, University of British Columbia
-
Graduate Student, University of Manitoba
-
Associate Professor & Chair of Eco-Entrepreneurship, McMaster University
-
Professor and Head, Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University
-
Professor of Health Economics, Flinders University
-
PhD student, University of Sydney
-
Research Assistant Professor of Pharmacy, University of Washington
-
Professor of Chemistry, Northeastern University
-
Associate Professor in Pharmacology, Flinders University
-
Doctoral Student in Biochemistry, University of Washington
